Intersect ENT beats Q3 sales estimates, raises full-year forecast

Shares in Intersect ENT (NSDQ:XENT) rose slightly today after the steroid-eluting implant maker beat sales expectations on Wall Street with its third quarter results. The Menlo Park, Calif.-based company posted a net loss of -$4.3 million on sales of $22.3 million for the 3 months ended Sept. 30, for sales growth of 21% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Intersect ENT beats Q3 sales estimates, raises full-year forecast appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Implants Otolaryngology Ear, Nose & Throat Pharmaceuticals Wall Street Beat intersectent Source Type: news